Global Isovaleric Acidemia Treatment Industry to potentially hit US$ 1,125.15 Million by 2033 as per FMI

Isovaleric Acidemia Treatment Industry

The global isovaleric acidemia treatment industry growth is expected to be valued at US$ 652.28 Million in 2023 and is projected to reach US$ 1,125.15 Million by 2033, trailing a CAGR of 5.6%. Mass spectrometry development coupled with chromatography has advanced the reliability and efficiency of Isovaleric Acidemia profiling and shows the key structures in medical fields. The bio-information provided by these technologies enables accurate disease diagnostics and the useful clinical ability to manage diseases. The benefits of high sensitivity, highly accurate, and high throughput metabolomics show substantial capability in disease treatment which will drive the market during the forecast period.

Moreover, increasing demand for one-time therapies for metabolic disorders and the rising prevalence of lifestyle diseases are the key factors that are anticipated to boost growth of this market. The increasing product approval by regulatory authorities is anticipated to drive growth of global metabolism drugs market. PYRUKYND is a first-in-class, oral PK activator and the first approved disease-modifying therapy for hemolytic anemia in adults with pyruvate kinase (PK) deficiency disease which will augment the therapeutic market in Isovaleric Acidemia.

Get Your Report Sample To Gain Comprehensive Insights! https://www.futuremarketinsights.com/reports/sample/rep-gb-16305

Also, growing research and development for development metabolism drugs is anticipated to drive market growth over the forecast period. However, major factors that hinder growth of the global inborn errors of metabolism market include clinical hold on trials by market players. Moreover, the research in personalized medicine and the continuous development of advanced analytical tools are further supporting the growth of the market across the globe.

Key Takeaways from the Market Study:

• North America is expected to dominated the market with a share of 41.8% in 2022.
• Asia Pacific is projected to be fastest growing market for Isovaleric Acidemia with a CAGR of 4.9% during the forecast period.
• China is estimated to dominate the industry in APAC with a market share of 41% by 2033.
• By Treatment type, L-Carnitine supplement is expected to lead the industry with a segment share of 79% during the assessment period.
• Adoption of Next gen technologies like Tandem mass spectrometry and Mrna in metabolic testing procedures will lead to market expansion.

“Rising Investments in research and development activities and fast adoption of next generation technologies will bolster the market footprint” -comments an FMI Analyst

Get The Information You Need By Connecting With Our Analyst! https://www.futuremarketinsights.com/ask-question/rep-gb-16305

Competitive Landscape:

Key players in the Isovaleric Acidemia Market are:

• Amgen
• Replimune Group Inc.
• Transgene SA
• Oncolys BioPharma
• Targovax
• Lokon Pharma
• Vyriad
• TILT Biotherapeutics
• VCNBiosciences
• DNAtrix

Some recent developments in this industry are:

• In 2020, Nutricia established a sustainable plant in the Netherlands. The Nutricia Cuijk plant was a massive investment that increased the volume of specialized infant formula and the market’s revenue generation.
• In June 2022, Mead Johnson & Company, LLC announced that it had been completely merged with Reckitt Benckiser Group plc (RB). With Reckitt Benckiser plc groups’ good innovation and marketing processes, it was expected that the Mead Johnson brand and business would continue to boom.
• On February 17, 2022, Maze Therapeutics, a company translating genetic insights into new precision medicines, announced the initiation of dosing in the company’s Phase 1 clinical trial of MZE001 in healthy volunteers. MZE001, an oral glycogen synthase (GYS1) inhibitor that aims to address Pompe disease by limiting disease-causing glycogen buildup, is being evaluated for the potential oral treatment of patients with late-onset Pompe disease.
• On May 15, 2020, Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel products for rare and ultra-rare diseases, announced positive initial data from the confirmatory third cohort and longer-term data from the first two cohorts of the ongoing Phase 1/2 study of DTX401, an adeno-associated virus (AAV) based gene therapy for the treatment of glycogen storage disease type Ia (GSDIa).

Ignite Innovation with Customization: Uncover the Possibilities in Our Report! https://www.futuremarketinsights.com/customization-available/rep-gb-16305

Key Segments Profiled in the Isovaleric acidemia treatment industry Survey:

By Treatment:

• L-Carnitine Supplements
• Glycine Supplements
• Others

By Region:

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East & Africa (MEA)

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube